| dc.contributor.author | Reid, Michelle | |
| dc.contributor.author | Balcı, Serdar | |
| dc.contributor.author | Bağcı, Pelin | |
| dc.contributor.author | Saka, Burcu | |
| dc.contributor.author | Pehlivanoğlu, Burçin | |
| dc.contributor.author | Erbarut Seven, İpek | |
| dc.contributor.author | Baştürk, Olca | |
| dc.contributor.author | Adsay, N. Volkan | |
| dc.date.accessioned | 2020-04-16T08:12:53Z | |
| dc.date.available | 2020-04-16T08:12:53Z | |
| dc.date.issued | 2020 | en_US |
| dc.identifier.citation | Reid, M., Balcı, S., Bağcı, P., Saka, B., Pehlivanoğlu, B., Erbarut Seven, İ. ... Adsay, N. V. (2020). Is it justifiable to move the grade-1 ki67 index cut-off from 3% to 5% for pancreatic neuroendocrine tumors as has been proposed? The cases that fall to 3-5% category have clinicopathologic characteristics closer to those > 5%. 109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) içinde (1673-1673. ss.). Los Angeles, CA, February 29-March 05, 2020. | en_US |
| dc.identifier.issn | 0893-3952 | |
| dc.identifier.issn | 1530-0285 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12511/5129 | |
| dc.description.abstract | Background: Grading of linear parameters into meaningful (clinically relevant) clusters is a well-known challenge. Recently several groupshave proposed to change the Ki67 index cut-off for grade 1 (G1) category for PanNETs from < 3% to < 5%. This proposal presupposes thatthe cases with Ki67 index of 3-5% are NOT clinically different than the 0-3% group and thus can be lumped together with the current G1 (0-3% cases), instead of their current home in the G2 category (> 3%). | en_US |
| dc.description.sponsorship | United States & Canadian Academy of Pathology | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | Nature Publishing Group | en_US |
| dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
| dc.subject | Pancreatic Neuroendocrine | en_US |
| dc.subject | Clinicopathologic | en_US |
| dc.subject | Ki67 Index | en_US |
| dc.title | Is it justifiable to move the grade-1 ki67 index cut-off from 3% to 5% for pancreatic neuroendocrine tumors as has been proposed? The cases that fall to 3-5% category have clinicopathologic characteristics closer to those > 5% | en_US |
| dc.type | conferenceObject | en_US |
| dc.relation.ispartof | 109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) | en_US |
| dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Ana Bilim Dalı | en_US |
| dc.authorid | 0000-0001-6830-7701 | en_US |
| dc.identifier.volume | 33 | en_US |
| dc.identifier.issue | Supplement: 2 | en_US |
| dc.identifier.startpage | 1673 | en_US |
| dc.identifier.endpage | 1673 | en_US |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
| dc.identifier.wosquality | Q1 | en_US |
